Loading...
Market
Story
Organon to Acquire Dermavant and VTAMA Cream in $175 Million APA Deal
Sep 18, 2024, 11:35 AM
Organon has announced its acquisition of Dermavant, including its innovative dermatologic therapy, VTAMA (tapinarof) Cream 1%. The deal includes an upfront payment of $175 million, with additional payments up to $1.2 billion based on sales milestones. An additional $75 million is contingent on VTAMA's approval in AtD. This acquisition, structured as an APA, highlights Organon's commitment to expanding its dermatology portfolio.
View original story
Similar markets
Less than $100 million • 25%
$100 million to $199 million • 25%
$200 million to $299 million • 25%
$300 million or more • 25%
Yes • 50%
No • 50%
Less than $100 million • 25%
$100 million to $199 million • 25%
$200 million to $299 million • 25%
$300 million or more • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Less than $500 million • 25%
$500 million to $799 million • 25%
$800 million to $1 billion • 25%
More than $1 billion • 25%
None • 25%
Up to $100M • 25%
$100M to $200M • 25%
Over $200M • 25%
Less than $100 million • 25%
$100 million to $300 million • 25%
$300 million to $500 million • 25%
More than $500 million • 25%
Less than $100 million • 25%
$100 million to $299 million • 25%
$300 million to $499 million • 25%
$500 million or more • 25%
None • 25%
Up to $100 million • 25%
Up to $200 million • 25%
Up to $400 million • 25%